204 related articles for article (PubMed ID: 15073681)
1. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins.
Barrientos LG; Lasala F; Otero JR; Sanchez A; Delgado R
J Infect Dis; 2004 Apr; 189(8):1440-3. PubMed ID: 15073681
[TBL] [Abstract][Full Text] [Related]
2. Development of treatment strategies to combat Ebola and Marburg viruses.
Paragas J; Geisbert TW
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):67-76. PubMed ID: 16441210
[TBL] [Abstract][Full Text] [Related]
3. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus.
Barrientos LG; O'Keefe BR; Bray M; Sanchez A; Gronenborn AM; Boyd MR
Antiviral Res; 2003 Mar; 58(1):47-56. PubMed ID: 12719006
[TBL] [Abstract][Full Text] [Related]
4. Drug targets in infections with Ebola and Marburg viruses.
Gene OG; Julia BE; Vanessa MR; Victoria WJ; Thomas GW; Lisa HE
Infect Disord Drug Targets; 2009 Apr; 9(2):191-200. PubMed ID: 19275706
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions.
Bausch DG; Sprecher AG; Jeffs B; Boumandouki P
Antiviral Res; 2008 Apr; 78(1):150-61. PubMed ID: 18336927
[TBL] [Abstract][Full Text] [Related]
6. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity.
Panchal RG; Reid SP; Tran JP; Bergeron AA; Wells J; Kota KP; Aman J; Bavari S
Antiviral Res; 2012 Jan; 93(1):23-9. PubMed ID: 22027648
[TBL] [Abstract][Full Text] [Related]
7. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus.
Garrison AR; Giomarelli BG; Lear-Rooney CM; Saucedo CJ; Yellayi S; Krumpe LR; Rose M; Paragas J; Bray M; Olinger GG; McMahon JB; Huggins J; O'Keefe BR
Antiviral Res; 2014 Dec; 112():1-7. PubMed ID: 25265598
[TBL] [Abstract][Full Text] [Related]
8. Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry.
Radoshitzky SR; Warfield KL; Chi X; Dong L; Kota K; Bradfute SB; Gearhart JD; Retterer C; Kranzusch PJ; Misasi JN; Hogenbirk MA; Wahl-Jensen V; Volchkov VE; Cunningham JM; Jahrling PB; Aman MJ; Bavari S; Farzan M; Kuhn JH
J Virol; 2011 Sep; 85(17):8502-13. PubMed ID: 21697477
[TBL] [Abstract][Full Text] [Related]
9. Filoviruses: recent advances and future challenges.
Bray M; Pilch R
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):917-21. PubMed ID: 17181407
[No Abstract] [Full Text] [Related]
10. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
11. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization.
Ji X; Olinger GG; Aris S; Chen Y; Gewurz H; Spear GT
J Gen Virol; 2005 Sep; 86(Pt 9):2535-2542. PubMed ID: 16099912
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
[TBL] [Abstract][Full Text] [Related]
13. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.
Towner JS; Paragas J; Dover JE; Gupta M; Goldsmith CS; Huggins JW; Nichol ST
Virology; 2005 Feb; 332(1):20-7. PubMed ID: 15661137
[TBL] [Abstract][Full Text] [Related]
14. Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease.
Babirye P; Musubika C; Kirimunda S; Downing R; Lutwama JJ; Mbidde EK; Weyer J; Paweska JT; Joloba ML; Wayengera M
BMC Infect Dis; 2018 Oct; 18(1):498. PubMed ID: 30285648
[TBL] [Abstract][Full Text] [Related]
15. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor.
Cheng H; Schafer A; Soloveva V; Gharaibeh D; Kenny T; Retterer C; Zamani R; Bavari S; Peet NP; Rong L
Antiviral Res; 2017 Sep; 145():24-32. PubMed ID: 28645623
[TBL] [Abstract][Full Text] [Related]
16. Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
Sokolova AS; Yarovaya OI; Zybkina AV; Mordvinova ED; Shcherbakova NS; Zaykovskaya AV; Baev DS; Tolstikova TG; Shcherbakov DN; Pyankov OV; Maksyutov RA; Salakhutdinov NF
Eur J Med Chem; 2020 Dec; 207():112726. PubMed ID: 32905862
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus.
Bixler SL; Bocan TM; Wells J; Wetzel KS; Van Tongeren SA; Dong L; Garza NL; Donnelly G; Cazares LH; Nuss J; Soloveva V; Koistinen KA; Welch L; Epstein C; Liang LF; Giesing D; Lenk R; Bavari S; Warren TK
Antiviral Res; 2018 Mar; 151():97-104. PubMed ID: 29289666
[TBL] [Abstract][Full Text] [Related]
18. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis.
Feldmann H; Volchkov VE; Volchkova VA; Klenk HD
Arch Virol Suppl; 1999; 15():159-69. PubMed ID: 10470276
[TBL] [Abstract][Full Text] [Related]
19. [Ebola hemorrhagic fever and Marburg virus disease: their virological and clinical aspects].
Hirabayashi Y
Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):85-9. PubMed ID: 10088344
[No Abstract] [Full Text] [Related]
20. Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: variable transduction related to cell type and culture conditions.
Kahl CA; Pollok K; Haneline LS; Cornetta K
Mol Ther; 2005 Mar; 11(3):470-82. PubMed ID: 15727944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
